
    
      This study aims to investigate the therapeutic efficacy of PIPAC using cisplatin and
      doxorubicin in women with first recurrent resistance ovarian cancer and disease progression
      with peritoneal carcinomatosis. The primary objective of this study is to determine the
      Clinical Benefit Rate (CBR) according to RECIST/GCOG criteria after three cycles of PIPAC
      with PIPAC cisplatin and doxorubicin
    
  